Cell And Gene Therapy: Research, Development & Regulatory Guidance

Title: Standard Operating Procedure for Collection, Evaluation, Documentation, and Reporting of Safety Events in Clinical Trials Introduction and Purpose The assessment of safety events and the accurate reporting of these events are fundamental aspects of conducting clinical trials. These processes are crucial for ensuring the safety and well-being of research participants. This Standard Operating Procedure (SOP) outlines the procedures for collecting, evaluating, documenting, and reporting safety events, including Adverse Events (AE), Serious Adverse Events (SAE), Unanticipated Problems (UP), and other relevant safety events during the course of a clinical trial. The Principal Investigator (PI) holds the primary responsibility for the overall conduct of the trial, safeguarding the rights, safety, and welfare of study subjects, and ensuring that the investigation adheres to the protocol, Good Clinical Practice (GCP), Institutional Review Board (IRB), Food and Drug Administration (FDA),...

 Title: Standard Operating Procedure for FDA-Regulated Investigational Device Exemption (IDE) Application Introduction and Purpose Conducting a clinical investigation, often referred to as a clinical trial, under the umbrella of an FDA-Regulated Investigational Device Exemption (IDE) application entails navigating a complex set of FDA regulations, requirements, and obligations. The FDA places the responsibility for ensuring compliance with these regulations, requirements, and obligations squarely on the sponsor of the IDE application, as delineated in 21 CFR Part 812, Subpart C. While sponsors of IDE applications are typically pharmaceutical and device companies, the FDA's IDE regulations extend the sponsorship eligibility to individuals, governmental agencies, or academic institutions (21 CFR Part 812.3). The primary purpose of this Standard Operating Procedure (SOP) is threefold: To assist in determining when an IDE is required. To provide guidance and resources to individuals co...

Title: Investigational New Drug (IND) Application and Clinical Investigation Policy Introduction and Purpose: The conduct of clinical investigations (clinical trials) under an FDA-Regulated Investigational New Drug (IND) application involves compliance with a complex set of FDA regulations, requirements, and responsibilities. The FDA holds the IND application sponsor accountable for ensuring compliance with these regulations (21 CFR Part 312, Subpart D). While pharmaceutical companies are typical IND sponsors, individuals, governmental agencies, and academic institutions may also serve as sponsors (21 CFR Part 312.3). This policy serves the following purposes: To assist in determining when an IND is necessary. To provide guidance and resources for individuals conducting clinical investigations, including sponsor-investigators, on obtaining an IND for the investigational drug. To outline the process for compassionate use (expanded access) and emergency use of investigational drugs. Defi...

 Title: Clinical Trial Monitoring Procedure Introduction and Purpose: The purpose of this Standard Operating Procedure (SOP) is to outline the requirements for conducting interventional clinical trials at the clinical site It serves as a guide to promote quality and ensure adherence to Good Clinical Practice (GCP) standards. This SOP may also be applied to other types of clinical research studies to maintain high standards of quality. Scope: This SOP applies to all personnel involved in the monitoring of ESCTs, including clinical monitors, site coordinators, investigators, and other relevant staff. Definitions and Acronyms: Clinical Research: Encompasses all research involving human participants, excluding secondary studies using existing biological specimens or data collected without identifiers or publicly available data. Clinical Trial: Refers to clinical research studies involving human participants assigned to an intervention designed to evaluate the effect(s) of the intervent...

 Title: Case Report Form (CRF) Data Entry Procedure for Clinical Trials Introduction and Purpose: Case Report Forms (CRFs) are essential documents, whether in paper or electronic format, designed to systematically record all protocol-required information and results for each participant in a clinical trial. Accurate and timely data entry into the CRF is critical for ensuring the trial's proper conduct, evaluating safety and efficacy endpoints, and forming the basis for trial-related reports and publications. This Standard Operating Procedure (SOP) establishes standards for the accurate and timely entry of data into CRFs for clinical trials, following International Council on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. These standards should be adhered to, unless the study contract or Clinical Trial Agreement (CTA) specifies more specific requirements. Definitions and Acronyms: Clinical Research: Encompasses all research involving human participants, excluding secon...

 Title: Informed Consent Procedure for Clinical Research Studies Introduction and Purpose: Informed consent is a fundamental component of ethical clinical research, ensuring that participants voluntarily agree to participate with full awareness of the study's purpose, procedures, and potential risks. This Standard Operating Procedure (SOP) outlines the procedures for obtaining and documenting informed consent for clinical research studies conducted at [Institution Name]. It is essential to adhere to federal regulations, including the Department of Health and Human Services Common Rule (45 CFR §46) and the U.S. Food and Drug Administration (FDA) regulations (21 CFR §50), as well as the International Council on Harmonization (ICH) Good Clinical Practice (GCP) guidelines, which provide guidance on obtaining informed consent. This SOP applies to all clinical research studies that require informed consent as outlined in 45 CFR §46 and 21 CFR §50 and do not fall under consent without sig...

 Title: Protocol Deviations Handling and Reporting Procedure Introduction and Purpose: Protocol deviations in clinical research, whether from the clinical research protocol, Good Clinical Practice (GCP) guidelines, or applicable federal regulations, have the potential to jeopardize the safety and rights of study participants and compromise the scientific integrity of the study. Therefore, it is crucial to identify, address, and correct deviations when possible, as well as to establish preventive measures to mitigate future occurrences. Deviations must be documented in accordance with GCP guidelines and reported to the Institutional Review Board (IRB) following the procedures outlined in this Standard Operating Procedure (SOP) and in compliance with IRB policies and procedures. The deviation reporting guidelines provided in this SOP pertain to studies overseen by the clinical site IRB. For studies under a Central IRB (CIRB) or another IRB of record, both the CIRB or IRB-specific dev...

 Title: Study Records Collection and Maintenance Introduction and Purpose: The purpose of this SOP is to define the procedures for collecting and maintaining study records in the conduct of clinical research at the clinical site and relevant covered entities. In accordance with FDA regulations and Good Clinical Practice (GCP) guidelines, it is essential to maintain original records of clinical findings, observations, and activities for the reconstruction and evaluation of clinical research studies. Subject-specific records, contained within study participant charts, serve as source documentation of research records. These records encompass various documents such as signed informed consent forms, medical histories, medication logs, treatment records, protocol assessment results, and records of adverse events. Additionally, general study records, including versions of the study protocol and informed consent form, Institutional Review Board (IRB) approvals, investigator's brochures, t...

Title: Investigator Delegation of Authority Introduction and Purpose: This Standard Operating Procedure (SOP) outlines the process by which the Principal Investigator (PI) delegates the authority to conduct clinical study procedures and tasks to sub-investigators and other study personnel. It also details the maintenance of documentation related to staff and investigator signatures and handwriting samples. Scope: The PI conducting a clinical trial must adhere to regulations governing informed consent (21 CFR 50) and regulations regarding Institutional Review Board (IRB) review and approval (21 CFR 56). If the study involves an investigational drug or device, additional regulations in 21 CFR 312 or 21 CFR 812 apply. Furthermore, all clinical study investigators should follow the International Council on Harmonization (ICH) guidelines for Good Clinical Practice (GCP). While these responsibilities are primarily held by the PI, they can be delegated to qualified sub-investigators and other...

 Title: Investigator Responsibilities Introduction and Purpose: The purpose of this Standard Operating Procedure (SOP) is to outline the requirements for conducting interventional clinical trials at the clinical site. This SOP can also serve as a guide for other types of clinical research studies, emphasizing the importance of quality and adherence to Good Clinical Practice (GCP) standards. Scope: The Principal Investigator (PI) of a clinical trial holds crucial responsibilities and obligations outlined in the Code of Federal Regulations (CFR) and Good Clinical Practice (GCP) guidelines. These responsibilities are essential to safeguard the rights, safety, and welfare of study participants and to ensure the credibility of study results. The PI of a clinical trial is mandated to adhere to regulations governing human subject protection, including obtaining informed consent from participants and obtaining Institutional Review Board (IRB) review and approval, as specified in United Sta...

 Title: Protocol Training for Investigators and Study Staff Introduction and Purpose: The purpose of this Standard Operating Procedure (SOP) is to establish the requirements for the conduct of interventional clinical trials within the clinical site. It may also serve as guidance for other types of clinical research studies to ensure adherence to Good Clinical Practice standards and maintain research quality. Scope: Before commencing clinical research, the Principal Investigator (PI), sub-investigators, and study staff must undergo training in various aspects, including the protection of human research participants, the handling of personal health information, Good Clinical Practice (GCP) guidelines, Conflict of Interest (COI) principles, and, when applicable, Biosafety Training. Furthermore, the PI and all study personnel must receive specific study/protocol training to ensure: Compliance with the investigational plan. Protection of the rights, safety, and welfare of study particip...

SOP on FDA Inspections at Clinical Sites Introduction and Purpose: The U.S. Food and Drug Administration (FDA) conducts inspections to ensure the rights, safety, and welfare of subjects involved in FDA-regulated clinical trials are protected, to determine the accuracy and reliability of clinical trial data, and to determine if the study has been conducted in compliance with FDA regulations. The most common type of inspection is classified by the FDA as a “Routine” inspection and is generally triggered by a marketing approval submission. Clinical sites with the highest enrollment numbers in the pivotal trials are the most likely candidates for a routine inspection. “For Cause” inspections are less common, and generally are conducted to investigate a specific problem that has come to FDA’s attention. The Office for Human Research Protections (OHRP) within the U.S. Department of Health and Human Services may also initiate and conduct inspections of clinical trials. The responsibilities, n...

 The guideline titled "Guideline on Clinical Trials in Small Populations" (CHMP/EWP/83561/2005) was issued by the European Medicines Agency (EMA). This guideline provides recommendations and guidance for conducting clinical trials for medicines intended for rare diseases or conditions affecting small populations. Here's an elaboration of the key points covered in this guideline: 1. Background: The guideline recognizes that traditional clinical trial designs may not be suitable for rare diseases or conditions, where patient populations are limited. Therefore, it aims to provide a framework for conducting meaningful and scientifically sound clinical trials in such scenarios. 2. Definition of a Small Population: The guideline doesn't provide a specific numerical definition of a small population but rather focuses on diseases or conditions that are rare or have a low prevalence. It acknowledges that the definition may vary by region and disease. 3. Ethical Considerations:...